Export
Model List of Essential Medicines
clear
Found 205 recommendations for 65 medicines and 3 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
-
Abiraterone General information
SectionHormones and antihormones- Oral > Solid: 250 mg; 500 mg
Indications -
Afatinib General information
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung -
All-trans retinoic acid General information
SectionTargeted therapies- Oral > Solid: 10 mg capsule
-
Allopurinol General information
SectionSupportive medicines- Oral > Solid: 100 mg tablet; 300 mg tablet
Indications -
Anastrozole General information
SectionHormones and antihormones- Oral > Solid: 1 mg tablet
-
Arsenic trioxide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion
-
Asparaginase General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
Indications -
Bendamustine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
-
Bicalutamide General information
SectionHormones and antihormones- Oral > Solid: 50 mg
Indications -
Bleomycin General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
-
Bortezomib General information
SectionTargeted therapies- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
Indications -
Calcium folinate General information
SectionCytotoxic medicines- Oral > Solid: 15 mg tablet; 5 mg tablet; 25 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
-
Capecitabine General information
SectionCytotoxic medicines- Oral > Solid: 150 mg tablet; 500 mg tablet
-
Carboplatin General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
-
Chlorambucil General information
SectionCytotoxic medicines- Oral > Solid: 2 mg tablet
-
Cisplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL
IndicationsOther specified malignant neoplasms of the ovary Osteosarcoma of bone and articular cartilage of unspecified sites Germ cell tumour of testis Other specified malignant neoplasms of bronchus or lung Squamous cell carcinoma of oropharynx Malignant neoplasms of cervix uteri Malignant neoplasms of nasopharynx -
Cyclophosphamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection
- Oral > Solid: 25 mg tablet; 50 mg tablet
IndicationsMalignant trophoblastic neoplasms of placenta Ewing sarcoma of bone and articular cartilage of unspecified sites Follicular lymphoma Other specified malignant neoplasms of breast Lymphoid leukaemia, NOS Chronic lymphocytic leukaemia or small lymphocytic lymphoma Malignant neoplasms of breast Rhabdomyosarcoma primary site Hodgkin lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphomas -
Cytarabine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
-
Dacarbazine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 100 mg in vial powder for injection
Indications -
Dactinomycin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 µg in vial powder for injection
-
Dasatinib General information
SectionTargeted therapies- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
Indications -
Daunorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
-
Dexamethasone General information
SectionHormones and antihormones- Oral > Solid: 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
Indications -
Docetaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
-
Doxorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
IndicationsMalignant neoplasms of breast Hodgkin lymphoma Other specified malignant neoplasms of breast Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Follicular lymphoma Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, NOS Plasma cell myeloma Kaposi sarcoma of unspecified primary site Diffuse large B-cell lymphomas -
Erlotinib General information
SectionTargeted therapies- Oral > Solid: 100 mg; 150 mg
-
Etoposide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule; 50 mg capsule
IndicationsOther specified malignant neoplasms of bronchus or lung Malignant trophoblastic neoplasms of placenta Germ cell tumour of testis Hodgkin lymphoma Other specified malignant neoplasms of the ovary Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, NOS Retinoblastoma -
Filgrastim General information
SectionImmunomodulators- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
Indications -
Fludarabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)
-
Fluorouracil General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
-
Gefitinib General information
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung -
Gemcitabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
-
Hydrocortisone General information
SectionHormones and antihormones- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
Indications -
Hydroxycarbamide General information
SectionCytotoxic medicines- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Indications -
Ifosfamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
-
Imatinib General information
SectionTargeted therapies- Oral > Solid: 100 mg tablet; 400 mg tablet
-
Irinotecan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
Indications -
Lenalidomide General information
SectionImmunomodulators- Oral > Solid: 25 mg
Indications -
Leuprorelin General information
SectionHormones and antihormones- Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
-
Melphalan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg
Indications -
Mercaptopurine General information
SectionCytotoxic medicines- Oral > Solid: 50 mg tablet
-
Mesna General information
SectionSupportive medicines- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
-
Methotrexate General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)
-
Methylprednisolone General information
SectionHormones and antihormones- Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
Indications -
Nilotinib General information
SectionTargeted therapies- Oral > Solid: 150 mg capsule; 200 mg capsule
Indications -
Nivolumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
Indications -
Oxaliplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
-
Paclitaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 6 mg per mL
IndicationsOther specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Kaposi sarcoma of unspecified primary site Malignant neoplasms of nasopharynx Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri -
Pegaspargase General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 3750 units per 5 mL in vial
Indications -
Pembrolizumab General information
SectionImmunomodulatorsIndicationsTherapeutic equivalent to nivolumab for Melanoma of skin -
Prednisolone General information
SectionHormones and antihormones- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg
-
Procarbazine General information
SectionCytotoxic medicines- Oral > Solid: 50 mg (as hydrochloride)
Indications -
Realgar-indigo naturalis formulation General information
SectionCytotoxic medicines- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
-
Rituximab General information
SectionTargeted therapies- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
-
Tamoxifen General information
SectionHormones and antihormones- Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
-
Thalidomide General information
SectionImmunomodulators- Oral > Solid: 50 mg
Indications -
Tioguanine General information
SectionCytotoxic medicines- Oral > Solid: 40 mg
Indications -
Trastuzumab General information
SectionTargeted therapies- Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
Indications -
Vinblastine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
-
Vincristine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
IndicationsKaposi sarcoma of other specified primary sites Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Follicular lymphoma Lymphoid leukaemia, NOS Rhabdomyosarcoma primary site Diffuse large B-cell lymphomas Retinoblastoma Hodgkin lymphoma Burkitt lymphoma including Burkitt leukaemia -
Vinorelbine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
-
Zoledronic acid General information
SectionSupportive medicines- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle